What We Do

Aiding customers and Collaborators in the development of Pharmaceuticals

IsoTherapeutics is a radiopharmaceutical development company that launched R&D services in 2005 to aid customers and collaborators in the development of pharmaceuticals. The company has earned a solid reputation in radiochemistry, radiolabeling, and process/product development.

IsoTherapeutics has recently enhanced its capabilities to help customers with cGMP radiopharmaceutical manufacturing for clinical trials. This helps ensure seamless development of products from research to clinical trial-stage manufacturing.

Work With Us

A variety of ways we work with our customers.

Usually, we perform fee-for-service early stage R&D meeting agreed upon deliverables. We are very flexible and are open to a variety of business models in which we can participate.

Our range of services include helping customers/partners with early stage research from proof of concept for a new chemistry or drug molecule through making of the drug in a cGMP facility for preclinical studies. These services include:


100+ years of collective experience

The company also plays an advisory role based on its 100+ years of collective experience. The company works with customers in a variety ways and engages with customers every step of the way with the final goal being reduction of costs and shortening of the time to clinical trial.

Our Clients & Partners

In the company’s short history, IsoTherapeutics has been able to serve a variety of customers including:

Got a Project? Let's Schedule An Appointment

Telix Expands U.S. Development and Manufacturing Infrastructure with Acquisition of IsoTherapeutics

Melbourne (Australia) – 9 April 2024. Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces the completion of the acquisition of IsoTherapeutics Group, LLC (IsoTherapeutics).

IsoTherapeutics is a privately held, commercial-stage company that provides radiochemistry and bioconjugation development and contract manufacturing services to numerous companies in the radiopharmaceutical industry, including Telix. The acquisition further enhances Telix’s in-house development capabilities and expands Telix’s United States (U.S.) manufacturing footprint with particular focus on bioconjugation and isotope processing.

Dr Christian Behrenbruch, Managing Director and Group CEO of Telix said, “The acquisition of IsoTherapeutics Group is a significant milestone in Telix’s continued focus on vertical integration of development, supply and manufacturing and is highly complementary to Optimal Tracers (Sacramento, California), ARTMS (Vancouver) and our extensive commercial manufacturing infrastructure in Belgium. In the IsoTherapeutics team, we have partnered with some of the leading experts in radiochemistry and I am excited at what we can achieve together going forward.”